Please assess the completion status of the following clinical trial:

Trial Title: Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus, type 2~* Treatment regimens: diet and exercise only or are taking metformin as monotherapy and are willing to discontinue this medication~* Have completed at least 8 weeks of wash-out prior to randomization (if on metformin therapy at screening)~* Have a qualifying glycosylated hemoglobin (HbA1c) value, as determined by the central laboratory: at screening (for diet and exercise only ≥7.0% to ≤9.5%; for metformin monotherapy \>6.5% to ≤9.0%) and at time of randomization for all participants ≥6.5% to ≤9.5%~* Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method~* Have a body mass index (BMI) between 23 and 40 kilograms/meter squared (kg/m\^2), inclusive, for participants who are native to, and reside in, South and/or East Asia; all other participants must have a BMI between 25 and 40 kg/m\^2, inclusive.~* Stable weight for 3 months prior to screening~Exclusion Criteria:~* Diabetes mellitus, type 1~* Taking any glucose-lowering oral agents other than metformin within 3 months prior to screening~* Use of glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or being treated within insulin (with the exception of short-term management of acute conditions that occurred more than 3 months immediately prior to screening)~* Use of medications (prescription or over-the counter) to promote weight loss~* Chronic (\>2 weeks) use of systemic glucocorticoid therapy~* Gastric emptying abnormality, history of bariatric surgery or chronic use of drugs that affect gastrointestinal motility~* Use of central nervous system (CNS) stimulant (for example, Ritalin-sustained release \[SR\])~* Cardiovascular event within 6 months prior to screening~* Poorly controlled hypertension (determined by a mean seated systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or mean seated diastolic BP ≥95 mmHg at screening or randomization)~* Electrocardiogram (ECG) reading considered outside the normal limits by the investigator and relevant for interpretation or indicating cardiac disease~* Liver disease, hepatitis, chronic hepatitis, or alanine transaminase levels \>3.0 times upper limit of normal~* Clinical signs or symptoms of pancreatitis or history of chronic or acute pancreatitis at time of screening~* Amylase ≥3 times the upper limit of normal and/or lipase ≥2 times upper limit of normal which are determined by central labs at the time of screening~* Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) for men or ≥1.4 mg/dL for women or a creatinine clearance \<60 milliliter (mL)/minute which are determined by central labs at the time of screening~* Uncontrolled diabetes (defined as 2 or more episode of hyperosmolar state requiring hospitalization in the 6 months prior to screening)~* Significant active, uncontrolled endocrine or autoimmune abnormality~* History of a transplanted organ (corneal transplants are allowed)~* Active or untreated malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years~* Have any other condition, in the opinion of the investigator, that may preclude the participant from following or completing the protocol~* Investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling, whether biological or legally adopted)~* Sponsor employees~* Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to entry into the study~* Have previously completed or withdrawn from this study after providing informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.1 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
- 0.5 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
- 1.0 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
- 1.5 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: subcutaneous (SC) once weekly (QW)

Based on this trial design, predict the completion outcome and termination type (if applicable).